STAT+: Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua

Data ReadoutnegativeWainuaNegative

AI Analysis

Summary

AstraZeneca's Wainua heart disease trial has failed, creating pressure on competitor Alnylam to defend its own heart disease drug candidates in the same therapeutic space.

Outcome Details

AstraZeneca heart disease trial failure

Importance:6/10

Sentiment:

-0.40

heart diseasetrial failureRNAicompetitive pressure

Related Companies

$ALNY $AZN

Read the original article

Published by STAT News on August 30, 2026 5:29 PM

Read Original